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Abstract 
 
As the use of molecularly targeted agents, which are anticipated to increase overall and 
progression-free survival (OS and PFS), but not necessarily tumor response, has 
increased in oncology, there has been a corresponding increase in the recommendation 
and use of randomized phase II designs.  Such designs reduce the potential for bias, 
existent in comparisons with historical controls, but also substantially increase the sample 
size requirements.  We review the principal statistical designs for historically controlled 
and randomized phase II trials, along with their advantages, disadvantages, and statistical 
design considerations.  We review the arguments for and against the use of randomization 
in phase II studies, the situations in which use of historical controls are preferred, and the 
situations in which use of randomized designs are preferred.  We review methods used to 
calculate predicted OS or PFS values from historical controls, adjusted so as to be 
appropriate for an experimental sample with particular prognostic characteristics.  We 
demonstrate how adjustment of the type I and type II error bounds for randomized studies 
can facilitate detection of appropriate target increases in median PFS or OS with sample 
sizes appropriate for phase II studies.  While there continues to be differences among 
investigators concerning the use of randomization vs. historical controls in phase II trials, 
there is agreement that each approach will continue to be appropriate, and the optimal 
approach will depend upon the circumstances of the individual trial. 
 
1. Introduction and statement of the problem 
 
Until recently, the phase II trial in oncology generally took the form of the single-arm  
two-stage design [1,2], for which the typical endpoint was objective tumor response, 
defined as shrinkage by at least 50% bi-dimensionally or 30% uni-dimensionally (by the 
RECIST guidelines [3]).  A two-stage design was frequently constructed to distinguish 
between a study-level response rate felt to indicate a lack of promise (often 5%) and a 
response rate that would indicate promising activity (often 20%) with one-sided type I 
error rate of 5-10% and type II error rate of 10%-20%.  (Please refer to Figure 1, at the 
end of the manuscript for statistical terms used.)  The dominant use of this design was 
based on the premise that an agent that could not produce a tumor response rate of 20% 
(or, for some diseases with minimally effective therapy already in place, 30% or 40%) 
was not likely to produce a clinically meaningful overall survival (OS) or progression-
free survival (PFS) benefit in subsequent phase III testing. 
 
The recent rapid evolution in oncology drug development has challenged these 
previously accepted paradigms.  Many phase II trials are now designed to assess the 
promise of a molecularly targeted agent, given either alone or in combination with 
another regimen.  In particular, it is not always anticipated that such agents are likely to 
produce or improve tumor response rates; rather that such agents will improve PFS or OS 
through means other than direct cell killing as evidenced by tumor shrinkage [4].  In 
addition, for many diseases, such as lung, colon, breast, and renal cancers [5,6,7], tumor 
response has failed to predict for a survival benefit, and for other diseases, such as 
glioblastoma and prostate cancer, tumor response has proven difficult to measure.  
Finally, recent papers have demonstrated that even with the use of standard cytotoxic 
therapy, patients without a tumor response benefit from superior therapy [8].  In general, 
PFS is the preferred endpoint for such phase II trials, since it is more statistically efficient 
than OS (because it is significantly shorter and the treatment effect is not diluted by 
salvage treatment).  For diseases with very short median OS and lack of effective salvage 
treatment, or where PFS cannot be reliably measured, OS may be a preferred endpoint, 
even in the phase II setting [9].  Such trials can be single-arm studies, with an endpoint of 
median PFS or OS, or PFS or OS may be measured at a particular time point, and then 
compared to that of historical controls.  Alternatively, such trials can be randomized.   
 
As the use of molecularly targeted agents, which are anticipated to increase OS and PFS, 
but not necessarily tumor response, has increased in oncology, there has been a 
corresponding increase in the recommendation and use of randomized phase II designs.  
Such designs reduce the potential for bias, existent in comparisons with historical 
controls, but also substantially increase the sample size requirements.   
 
In this paper, we will discuss the statistical issues concerning the use of randomized 
versus non-randomized phase II designs in the context of these various current 
challenges.  We review the principal statistical designs for historically controlled and 
randomized phase II trials, along with their advantages, disadvantages, and statistical 
design considerations.  We review the arguments for and against the use of randomization 
in phase II studies, the situations in which use of historical controls are preferred, and the 
situations in which use of randomized designs are preferred.  We review methods used to 
calculate predicted OS or PFS values from historical controls, adjusted to be appropriate 
for an experimental sample with particular prognostic characteristics.  We demonstrate 
how adjustment of the type I and type II error bounds for randomized studies can 
facilitate detection of appropriate target increases in median PFS or OS with sample sizes 
appropriate for phase II studies.  While there continues to be differences among 
investigators concerning the use of randomization vs. historical controls in phase II trials, 
there is agreement that each approach will continue to be appropriate, and the optimal 
approach will depend upon the circumstances of the individual trial. 
 
2. Historically controlled studies 
 
While adequate historical benchmarks may exist for objective tumor response, which is 
thought to be relatively unaffected by individual patient prognostic factors, such data may 
not be available for PFS or OS, particularly for subsets of patients expressing a particular 
marker or target, or where prognostic factors may vary between experimental and control 
patient samples.  For this reason, phase II trials with time-to-event endpoints (PFS or OS) 
are often randomized.  However, there are also strong reasons why statisticians and 
clinicians sometimes resist the use of randomized control groups in phase II trials.  
Perhaps the strongest reason is statistical efficiency.  If there is high confidence that the 
historical data concerning PFS or OS fairly represent what would be expected of the 
experimental group treated in the standard manner, then evaluating the results with an 
experimental agent or regimen can be done with half the patients or less, by using 
historical controls rather than randomizing against a control group.  This is true even if 
there is not access to individual patient historical data, but only the median survival, or if 
the number of patients in the historic series is limited.  Brookmeyer and Crowley [10] 
give methodology for comparing against historic data, and calculating the required 
sample size, when only the median survival is available.  Rubinstein et al [11] give 
methodology for calculating the required sample size for randomized studies using the 
logrank statistic.  Korn and Freidlin [12] show how this approach can be extended to one-
armed studies compared against historical controls, if the patient data are available. 
 
The most significant concern with using historical controls to assess PFS or OS in a 
single-arm phase II trial of an experimental treatment is that the historical controls may 
not fairly represent the expected outcome of the experimental patients, if given standard 
treatment.  In other words, the historical control patients may be inherently inferior or 
superior in terms of expected PFS or OS, due to differences with respect to at least three 
factors.  First, the expected outcomes for standard of care may change over time, due to 
improvements in supportive care, earlier detection, differences in radiological assessment 
techniques, greater availability of second line therapy (if the endpoint is OS), or other 
reasons.  Second, the inter-institution variability in outcomes has been shown to be large 
in many settings, thus if the new trial enrolls patients from different institutions, or in a 
different ratio from the same institutions, the historical data may be inaccurate.  Finally, 
the patients on the new trial may differ from the patients in the historical studies due to 
differences in prognostic factors [13].  If the important prognostic factors associated with 
clinical outcome in the patient population can be identified, this problem may be partially 
addressed, as demonstrated by Korn et al [14].  Using a large meta-analysis of melanoma 
patients treated on phase II studies, they identify the important prognostic variables and 
their contributions to one-year OS and six-month PFS rates, as well as to the survival 
distributions for either time-to-event endpoint.  This allows them to construct tests of the 
observed one-year OS and six-month PFS rates, or of the respective observed survival 
distributions, associated with a one-armed test of an experimental regimen, adjusting for 
the particular mix of prognostic factors in the experimental population. This effort is 
currently being extended to advanced non-small cell lung cancer, and metastatic 
pancreatic cancer.  However, even in a detailed meta-analysis of individual patient data, 
the proportion of variability explained by the observed covariates is often limited.  
Finally, standard single-arm designs, such as the Simon design, assume that the historical 
response rate is known, as opposed to the reality that this response rate is an estimate 
with associated variability. 
 
 
3. Randomized studies 
 
For several decades, there has been increased interest in randomized designs for phase II 
studies in oncology.  An increasing number of new agents are biologic or molecularly 
targeted, and thus are anticipated to yield increased PFS or OS but not necessarily 
increased tumor shrinkage [4], alone or, more likely, in combination with standard 
regimens.  PFS or OS is affected by patient characteristics (not always identifiable) which 
may vary between a new experimental sample and historical control patients.  In addition, 
there is a strong argument for randomization for studies in which the endpoint has been 
collected differently or inconsistently in the past or is absent from historical data sets. For 
instance, this could be an endpoint which includes biochemical measures, such as PSA 
progression in prostate cancer [13].  On the other hand, for some diseases it may be more 
difficult to accrue patients to a randomized study compared to a non-randomized study at 
the phase II stage of drug development due to patient and/or physician preferences.  Also, 
in rare disease settings accrual is a problem.  Randomized designs generally require as 
much as four times as many patients as single-arm studies, compared to historical 
controls, with similar theoretical statistical operating characteristics.  Therefore, there has 
been a series of attempts to develop randomized designs that offer some protection 
against the uncertainties and potential biases of one-armed studies, while retaining some 
of the statistical efficiency. 
 
One early attempt by Herson and Carter [15] involved randomizing a portion of the 
patients to a small reference arm.  The experimental arm would not be compared to the 
reference arm; it would be analyzed against historical controls as if it were a one-armed 
study.  The reference arm in this design was intended to only act as a check on the 
similarity of the current patients to the historical controls with respect to clinical outcome 
when given the standard treatment.  The disadvantages of this sort of approach are that 
the reference arm is too small for its outcome to truly assure comparability for the 
experimental group, since there is little power to reliably detect a moderate but clinically 
meaningful lack of comparability.  If, in this design, the reference arm has outcome 
substantially different from that expected based on historical controls, it is often difficult 
to interpret the outcome of the experimental arm.  If the reference arm does very poorly 
compared to controls, an apparently negative outcome for the experimental arm may be 
due to inferior prognosis for the patients.  Conversely, if the reference arm does very well 
compared to controls, an apparently positive outcome for the experimental arm may be 
due to superior prognosis for the patients.  This is a generic problem with attempting to 
incorporate a randomized control arm into a phase II trial that is not large enough to 
allow for direct comparison, to reduce the associated cost in increased sample size. 
 
A second early attempt by Ellenberg and Eisenberger [16] involved incorporating a 
randomized phase II trial as the initial stage in a phase III protocol.  The proposal was to 
terminate the phase III study only if the experimental arm demonstrated inferior tumor 
response rate to that of the control arm in the phase II stage.  In this design, the phase II 
sample size was specified to be sufficiently large so that there was only a 5% chance that 
an inferior response rate would occur if the true experimental response rate was superior 
by some pre-defined amount (this approach could be generalized to use of a PFS 
endpoint).  The disadvantage of this approach is that if the experimental treatment offers 
no true increase in tumor response rate, the phase III trial will still proceed beyond the 
initial phase II stage with .50 probability.  In other words, the initial phase II stage is 
operating at the .50 significance level.  This is a generic problem with randomized phase 
II/III designs; it is very difficult to operate at an appropriate type I and type II error rate 
without having a large sample size for the phase II portion.  This sort of design is 
appropriate if the investigators are already reasonably certain that the experimental 
treatment is sufficiently promising to justify a phase III trial, but wish to build into the 
trial a check on that assumption.  Thall [17] provides a good review of randomized phase 
II/III designs; see also Goldman, LeBlanc and Crowley [18]. 
 
3.1. Selection designs 
 
There is one context in which the use of a randomized phase II design can achieve its 
statistical objectives while maintaining a relatively small sample size, which is the case of 
directly comparing two experimental regimens, primarily for the purpose of prioritizing 
between the two.  Simon et al [19] formalized such pick-the-winner selection designs, 
where the regimen with a superior observed response rate (by any amount) is chosen, 
among the two, for further testing.  The original designs were constructed to yield 90% 
power to detect the superior regimen if the true difference between the response rates was 
15% (in absolute terms).  The weakness in the original design is that it does not assure 
that the (sometimes nominally) superior experimental regimen is superior to standard 
therapy.  It was occasionally argued that an ineffective experimental regimen could act as 
a control arm for the other regimen, but the design was not constructed to be used in this 
way, since, as designed, one of the two experimental regimens would always be chosen 
to go forward, even if neither was superior to standard treatment.  To address this, in 
practice, each arm of the selection design is generally constructed as a two-stage design, 
to be compared separately against a historically defined response rate (Liu, Moon and 
LeBlanc [20]).  However, that approach requires that it be possible to compare the 
experimental regimens to historical controls; this, as we have argued above, is not always 
the case. 
 
Where the randomized phase II selection design is appropriate, it can be conducted with 
modest sample size.  For example, Simon et al demonstrate that only 29-37 patients per 
arm will yield 90% power to detect a regimen that has response rate superior by 15%, in a 
two armed study.  This approach can be adapted to randomized phase II trials with time-
to-event (PFS or OS) endpoints, where the logrank test is used to choose between the two 
regimens, with dramatic results (Liu, Dahlberg and Crowley [21]).  Rubinstein et al [11] 
show that the required sample size for such trials is proportional to (z∀ + z∃)2 where z∀ 
and z∃ are the standard normal values associated with the type I and type II error bounds, 
respectively.  This means that if the type I error is set to .5 (z∀= 0), as it is for the 
selection design, then, compared to a randomized study with z∀= z∃ (which is standard 
for phase 2 designs) with the same targeted hazard ratio, the sample size is reduced by a 
factor of 4.  This also means that selection designs constructed to detect a hazard ratio 
(control hazard/experimental hazard) of 1.5 with 90% power are approximately equal in 
size (approximately 65 patients total) to the original selection designs constructed to 
detect a response rate difference of 15% with 90% power.   
 
3.2. Screening design of Rubinstein et al [22] 
 
None of the randomized phase II designs described above fully address the problem 
outlined in the beginning of section 3 – the increasing need in oncology to evaluate 
agents that are anticipated to increase PFS or OS, but not objective tumor response, 
primarily in combination with standard regimens, where comparison to historical controls 
may be problematic [4].  The reference arm and phase II/III designs have serious 
disadvantages, as outlined, and the selection design is meant for the limited situation 
where experimental regimens are to be compared for prioritization purposes, but, in 
general, each must also prove itself against historical controls.  For this reason, 
Rubinstein et al [22], building on previous work by Simon et al [23] and Korn et al [24], 
(and similarly to Fleming [25]) formalized the randomized phase II screening design.  
The intention was to define randomized phase II designs that yielded statistical properties 
and sample sizes appropriate to phase II studies.  They were meant to enable preliminary 
comparisons of an experimental treatment regimen, generally composed of a standard 
regimen with an experimental agent added, to an appropriate control, generally the 
standard regimen. 
 
Table 1 illustrates the statistical properties of such designs when the endpoint is PFS (or 
OS), and the logrank test is used.  The table provides the required numbers of failures for 
various type I and type II error rates appropriate to phase II trials, and for various targeted 
hazard ratios (control hazard/experimental hazard).  In general, it is expected that phase II 
studies will be conducted in patients with advanced disease, where most patients will 
progress within the trial period, so the required number of failures closely approximates 
the required number of patients.  (For example, if (α,β)=(10%,10%) and Δ=1.75 (median 
PFS is 5.25 vs. 3 months), and if accrual is over 1.5 year, with follow-up of 6 months, 
only 96 patients are required to observe 84 events, and similarly for the other items in the 
table.)  In the setting of the randomized trial, the usual limits for type I and type II errors 
may be stretched; in fact, usage of type I error of .20 may be cautiously considered.  It 
can also be noted that restricting the trial to a total sample size no greater than 
approximately 100 patients requires the targeted hazard ratio to be at least 1.5. 
 
Table 1. Approximate required numbers of observed (total) treatment failures for 
screening trials with PFS endpoints, using the logrank test 
 
  Hazard Ratios (Δ)  
Error rates Δ=1.3 Δ=1.4 Δ=1.5 Δ=1.75 
(α,β)=(10%,10%) 382 232 160 84 
(α,β)=(10%,20%) 
or (20%,10%) 
262 159 110 58 
(α,β)=(20%,20%) 165 100 69 36 
Note: Calculations were carried out using nQueryAdvisor 5.0 software (Statistical 
Solutions, Saugus, MA) based on methods given in Collett [26] with 1-sided α 
 
Table 2 illustrates the statistical properties of such designs when the endpoint is PFS rate, 
measured at a prespecified time point, and the binomial proportion test is used.  The table 
provides the required numbers of patients for various type I and type II error rates and for 
various targeted PFS rate differences (with the equivalent hazard ratios, calculated under 
the assumption of exponentiality).  The table reflects that the binomial proportion test, in 
general, is quite statistically inefficient in comparison to the logrank test.  In fact, for the 
same targeted hazard ratio, the comparison of PFS rates at a particular time point requires 
approximately twice as many patients.   Comparing PFS at a particular time point rather 
than across the entire survival curve means that restricting to a total sample size no 
greater than approximately 100 requires the targeted hazard ratio (control 
hazard/experimental hazard) to be at least 1.75.  Nevertheless, comparing PFS at a pre-
specified time is often done since PFS is often considered to be an endpoint that is 
difficult to measure, potentially subject to investigator bias, or influenced by differential 
follow-up between the treatment arms.  
 
Table 2. Approximate required numbers of total patients for screening trials with PFS 
rate (at a specified time) endpoints, using the binomial proportion test 
 
 PFS Rates (at a given time point, with equivalent hazard ratios )) 
Error rates 20% vs. 35% 
()=1.53) 
20% vs. 40% 
()=1.76) 
40% vs. 55% 
()=1.53) 
40% vs. 60% 
()=1.79) 
(α,β)=(10%,10%) 256 156 316 182 
(α,β)=(10%,20%) 
or (20%,10%) 
184 112 224 132 
(α,β)=(20%,20%) 126 78 150 90 
Note: Calculations were carried out using nQueryAdvisor 5.0 software (Statistical 
Solutions, Saugus, MA) based on methods given in Fleiss et al [27] with 1-sided α 
 
3.3 Randomized discontinuation design 
 
Rosner et al [28] propose a randomized discontinuation design that initially treats all 
patients with the study agent for a defined time period, and then randomizes patients with 
stable disease to continuation or discontinuation for a defined period to assess the effect 
of the drug in a population of presumably responsive and more homogeneous patients 
(Figure 3).  This design is probably most appropriate in situations where the treatment is 
such that significant continued benefit after initial benefit, in general, implies significant 
benefit overall, and vice versa.  Freidlin and Simon [29] argue that in many settings this 
design is less efficient than a standard randomized study, due to the large number of 
patients who must be treated initially, and thus a large number of patients may be 
unnecessarily exposed to a potentially non-efficacious treatment.  An additional problem 
with this design is that it may be difficult to define an appropriate population for further 
study in the event that the trial is positive.  However, Freidlin and Simon [29] also show 
that for the case where a non-identifiable subgroup of patients derives benefit from the 
treatment, this design may be useful.   
 
3.4. PFS vs. OS in randomized phase II studies 
 
There are significant advantages to using PFS as the primary endpoint rather than OS in 
randomized phase II studies.  Time-to-progression is shorter than time-to-death, 
sometimes substantially, so that the PFS endpoint yields more failures and thus greater 
power for the logrank test.  Hazard ratios for PFS are generally greater than for OS, again 
yielding greater power for the logrank test.  Finally, a positive phase II result based on 
PFS is less likely to complicate randomization to the definitive phase III study than a 
positive phase II result based on OS.  There are, however, also significant disadvantages 
to using PFS as the primary endpoint [4].  Sometimes PFS is difficult to measure reliably.  
There may also be concern that evaluation of the endpoint is influenced by investigator 
treatment bias or differential follow-up by treatment (if the control patients are followed 
more or less vigilantly, this may bias the observed time of progression).  In some cases, 
the issues of bias can be addressed effectively by blinding the study.  If this is not 
possible, at least the bias associated with differential follow-up can be addressed by using 
a comparison based on PFS rate at a pre-specified time, rather than using the logrank test.  
However, as we have demonstrated in section 3.2, this results in substantial loss of 
statistical efficiency.  Freidlin et al [30] address this problem by proposing a statistic 
based on comparing the two treatment arms at two pre-specified time points.  They 
demonstrate that this approach, which also promises to minimize bias due to differential 
treatment follow-up, recovers most of the efficiency lost in comparison to the logrank 
test. 
 
 
4. Discussion 
 
It must be emphasized that a randomized phase II study should almost never be taken as 
definitive evidence for the superior efficacy of an experimental agent or regimen.  
Rubinstein et al [22] and Fleming et al [25] suggest that the p-value must be less than 
.005 or smaller (a standard cut-off for phase III interim monitoring) for the phase II trial 
to preclude the necessity for conducting a definitive phase III successor study.  Liu et al 
[31] demonstrate that small randomized phase II studies can yield substantial false 
positive rates as well as substantially exaggerated estimated treatment effects.  Moreover, 
as argued by Redman and Crowley [32], in settings where adequate historical controls 
exist, historically controlled phase II studies are more efficient than randomized studies.  
Taylor et al [33] explore the performance of one-arm vs. two-arm phase II trials, using a 
tumor response endpoint, and conclude that two-arm trials may be superior if the sample 
size is larger (80 vs. 30 patients) and the uncertainty in the historical response rate is 
relatively high; in other cases, a single arm trial is generally preferred. 
 
The increased use of randomized phase II trials has been recommended by European 
[34,35] and American [22,36] investigators over the past decade, particularly for trials of 
experimental agents combined with standard regimens, with PFS as the endpoint.  In a 
recent review [37] of single-agent phase II trials of molecularly targeted agents, 30% (27) 
of 89 reported phase II trials were randomized, but only 3% (3) utilized placebo or 
standard agent controls.  An international task force [38] recommended that in “select 
circumstances”, randomized phase II studies of targeted anticancer therapy are “helpful to 
define the best dose or schedule, or to test combinations”, but single arm phase II studies 
continue to be appropriate “when the likely outcomes in the population studied are well 
described”.  In an accompanying editorial, Ratain et al [39] took a stronger position, 
strongly recommending that randomized phase II trials “become a standard approach in 
oncology, especially for the development of drug combinations.”  Our own 
recommendations concerning the various phase II designs discussed are briefly 
summarized in Figure 2, but this summary should not be used in lieu of the more nuanced 
recommendations given above.  While there continues to be differences among 
investigators concerning the use of randomization vs. historical controls in phase II trials, 
there is agreement that each approach will continue to be appropriate, and the optimal 
approach will depend upon the circumstances of the individual trial.   
 
Figure 1: Statistical terms used with respect to phase II clinical trials 
 
 
Historical 
controls 
Patients treated previously (or not, if no standard treatment is available) 
who are used as a standard for comparison with patients currently treated 
on an experimental regimen.  Such patients should be otherwise similar to 
the experimental patients. 
Type I error 
(∀) 
The probability of mistakenly calling an experimental treatment superior 
when, in fact, it is no better than the standard treatment (or no treatment, 
if there is no standard).  The “significance level” associated with a 
particular outcome is the type I error probability associated with that 
outcome. 
Type II error 
(∃) 
The probability of mistakenly calling an experimental treatment non-
superior when, in fact, it is superior to the standard by a pre-defined target 
difference.  The “power” of a trial to detect the target difference is 1 
minus the type II error. 
Z∀ and Z∃ The standard normal distribution values for which the probability of 
falling above the value is ∀ or ∃, respectively.  For example, Z.05 = 1.645. 
Binomial 
proportion 
test 
In randomized studies, the statistical test used to determine whether the 
proportion (rate) of tumor responses associated with an experimental 
treatment is greater than that associated with the standard treatment (or no 
treatment, if there is no standard). 
Hazard ratio Often used when constant instantaneous failure rates (“hazards”) are 
assumed for the two treatments – the ratio between the standard and 
experimental treatment hazards.  (Failure is usually defined as disease 
progression.)  When the hazards are constant, the hazard ratio is also the 
ratio between the median times to failure for the experimental vs. standard 
treatments.  The hazard ratio may be generalized to the situation where 
the ratio, but not the individual hazard rates, is constant over time. 
Logrank test In randomized studies, the statistical test used to determine whether the 
hazard rate associated with an experimental treatment is less than that 
associated with the standard treatment, where failures may be censored by 
loss-to-follow-up or end-of-study. 
 
Figure 2: Summary of phase II trial designs 
 
 
Trial design Pros, cons and appropriate usage 
Historical controls Appropriate for most trials with a tumor response endpoint.  
Minimizes required sample size but may be misleading, for a PFS 
endpoint, if experimental patients differ from the historical controls 
in important prognostic factors, quality of care, or extent of follow-
up.  It may be possible to statistically adjust for important covariates 
if such information is available for both experimental and historical 
control patients. 
Reference arm Randomization to a small reference control arm may afford a 
modest degree of re-assurance that the historical controls are 
appropriate, but the ability to detect differences between the 
reference arm and historical controls is limited, and any such 
detected differences can not be easily adjusted for.  In general, this 
design is not recommended. 
Phase II/III trial Makes efficient use of the patients by incorporating a phase II early 
look in a phase III trial, in cases where an additional check is 
desired for an otherwise very promising experimental regimen.  In 
general, this design is not recommended for phase II screening.  
Selection (pick-
the-winner) design 
An efficient and effective way of comparing two experimental 
regimens, usually incorporating comparisons of each with historical 
controls, and usually involving a tumor response endpoint.  This 
design is generally not appropriate for evaluating the addition of an 
experimental agent to a standard regimen. 
Screening design Limits the sample size required for a randomized phase II 
comparison by appropriately adjusting the type I and II error rates 
and the target difference.  Particularly appropriate for evaluating the 
addition of an experimental agent to a standard regimen, and when 
using a PFS endpoint. 
Randomized 
discontinuation 
design 
Appropriate when significant continued benefit after initial benefit, 
in general, implies significant benefit overall, and vice versa.  May 
be appropriate when benefit is restricted to a non-identifiable 
subgroup of patients, but may also subject a large number of 
patients to a treatment not effective for them.   
 
 
 
Figure 3: Randomized Discontinuation Design
Treat all patients initially on the experimental regimen 
for a defined period of time
Randomize only those that remain stable 
(patients who progress are taken off study and patients who respond continue 
to receive the experimental regimen)
Placebo Experimental
Compare placebo vs. experimental regimen from time of randomization
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